Medtronic has mitigated the impact of COVID-19 on its revenues by taking market share from competitors in key markets, including neurostimulation, drug-eluting stents, cardiac rhythm management and robotic spine surgery.
Medtronic Claims Share Gains In Cardiovascular And Neurostim
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
